Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline issues update on H1N1 vaccine orders

GlaxoSmithKline issues update on H1N1 vaccine orders

5th August 2009

GlaxoSmithKline has issued an update on governmental orders for the H1N1 vaccine.

The firm explained that it is committed to offering support to health authorities and governments around the globe as they respond to the swine flu pandemic.

It noted that on July 22nd, contracts were in place to provide some 195 million doses of its influenza vaccine, as well as an agreement with the US government to supply pandemic products worth $250 million (147.8 million pounds).

Since then, nine new government contracts have been signed, relating to an additional 96 million doses of the H1N1 vaccine, bringing the total number of doses ordered to 291 million.

“Discussions continue with governments for further supplies of the vaccine,” GlaxoSmithKline concluded.

In recent days, the company, along with Genmab, announced positive initial phase III trial results for ofatumumab administered intravenously for the treatment of rheumatoid arthritis in people who did not have an adequate response to methotrexate.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.